But Mr. deSoto, who has done his share of auto modifications, is unfazed.
The reduced PARP-1 auto-modification was associated with increased cell death and mortality under conditions that trigger PARP-1 induced cell death.
Notably, the major PAR acceptor is PARP-1 itself, which appears to accumulate roughly 90% of cellular PAR via PARylation of its auto-modification domain (AMD) [1].
15 glutamates are present in the AMD, representing roughly 50% of the total possible auto-modification targets in PARP-1: of these, 9 are in the BRCT portion [44] [47], and the other 6 in the nBD protion.
Cells treated with MNNG showed a distinct band of PAR immunoreactivity at 116 kD, corresponding to PARP-1 auto-modification, along with less distinct labeling of proteins at a range of molecular weights, generally above 85 kD (Fig. 3B, D).
Surprisingly, cells from these mice showed evidence of reduced, rather than increased auto-modification of PARP-1, possibly due to abnormal interaction between the truncated PARG and PARP-1 or XRCC1 [20], [35], [35].
Given that PARP-1 can be inhibited by PAR auto-modification [2], it is possible that the reduced peak PAR level observed in the PARG antisense-treated cultures is due to increased or prolonged PAR formation on PARP-1 with resultant reduced PARP-1 activity in these cultures.
Given what is known about PARP-1 cell death pathway, possibilities include 1) slowed PAR liberation from the nucleus [4] ; 2) slowed NAD+ consumption, due to reducing PAR turnover at acceptor sites or to increased PARP-1 auto-modification [5]; and 3) effects on PAR-regulated transcription factors [40].
NAD-dependent alteration of chromatin structure through Parp-1 auto-modification was demonstrated to lead to activation of estrogen induced estrogen receptor dependent transcription [ 12].
Parp-1 is activated by DNA damage and synthesizes PAR onto itself in an auto-modification reaction, which initiates DNA repair mechanisms (Berger, 1985; Benjamin and Gill, 1980).
PARP1 is the main acceptor for poly(ADP-ribosyl)ation in vivo and auto-modification of PARP1 abolishes its affinity for NAD+ and DNA [ 24, 25].
